Clinical and Molecular Hepatology

Article	Citations
Preface	614
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	613
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus	558
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign	378
Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver dise	295
Letter to the editor on “Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASLD”	276
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer	210
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023	205
Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”	204
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis	147
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity	146
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation	133
Navigating Discordant Noninvasive Fibrosis Assessments in MASLD: Implications for Generalizability, Clinical Decision-Making, and Resource Allocation	132
Reply to Correspondence: Advancing Immune-Informed and Subgroup-Stratified Research on the MET-TRIB3 Axis	117
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future	91
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)	89
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials	88
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity	85
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement	85
Ethanol‑Specific Stress and RAB25/GCN1 Signaling: Emerging Perspectives in Alcohol‑Associated Liver Disease	83
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A	76
Clinical applications of immunogenomics in hepatocellular carcinoma	74
HCC surveillance after curative treatment: A new frontier for abbreviated MRI: Editorial on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after cura	74
Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma	73
Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates	71

Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	69
Aspirin on the prevention of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease	67
Rethinking Lean Metabolic Dysfunction-Associated Steatotic Liver Disease: Unrecognized Risk in Lean Populations	66
Response to Editorial on “MicroRNA isomiRs reveal novel pathways linked to disease activity and fibrosis in MASLD”	65
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma	63
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c	61
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma	60
Toward hepatitis C virus elimination using artificial intelligence	58
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma	58
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target	57
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	57
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023	57
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment	56
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease	55
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial	55
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study	55
Reply to correspondence on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”	54
2025 KASL clinical practice guidelines for management of hepatitis C	54
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs	53
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate	53
Liver organoids: Current advances and future applications for hepatology	53
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	52
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”	50
What is new in the 2024 Chinese guidelines for fatty liver disease?	50
Reply to correspondence: Sodium-Glucose Cotransporter-2 Inhibitors and Liver Outcomes in Metabolic Dysfunction-associated Steatotic Liver Disease	50
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunothe	50
Correspondence to letter to the editor on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparis	49
Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation	49
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients wi	46
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review	45
A decade of liver organoids: Advances in disease modeling	44
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology	44
Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment	43
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program	43
Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”	42
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease	42
Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	39
Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”	39
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”	37
Plasma lipidomic and fungal signatures predict early mortality in acute liver failure	36
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated	36
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies	36
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study	36
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality	36
From Post-Transplant Outcomes to Listing Decisions: Clinical Implications of Comparing Expanded HCC Transplant Criteria	35
Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies	35
Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C	34
Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma	34
Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver d	33
Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy	33

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease	33
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?	32
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly	32
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The	31
Berberine and the gut microbiota - A novel treatment strategy for cholestatic liver disease	31
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”	31
Rethinking ACLF Prognosis: Can Machine Learning Outperform Conventional Scores? Editorial on: Predictive Machine Learning Model in ICU Patients with Acute-on-Chronic Liver Failure and Two or More Orga	31
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”	31
Precision Chemotherapy in Biliary Tract Cancer moving From Empiric Intensification to Biomarker-Guided Treatment: Editorial on “Molecular determinants of outcome to gemcitabine, cisplatin, and nab-pac	30
Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma	30
Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhib	30
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis	29
Discordant FIB-4 and Liver Stiffness in MASLD as related to Histology and Liver-Related Events in a Global Cohort	29
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression	29
Global incidence and prevalence of nonalcoholic fatty liver disease	28
Immunopathogenesis of liver fibrosis in steatotic liver disease	28
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogue	28
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity	28
New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?	28
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences	27
Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load	27
Acute-on-chronic liver failure: Terminology, mechanisms and management	27
Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma	27
Interaction between sarcopenia and nonalcoholic fatty liver disease	27
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways	27
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients	26
Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	26
A new Korean nomenclature for steatotic liver disease	26
Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohe	26
A cost-effectiveness evaluation framework for treatment for metabolic dysfunction-associated steatohepatitis: potential and concerns	26
Mendelian randomization does not support the effects of G CSF on decompensated liver disease	26
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”	25
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma	25
Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score?: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and no	25
Pediatric metabolic dysfunction–associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation	25
Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using vibration-controlled transient elastography: A systemic review and meta-analysis	25
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial	24
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association	24
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”	24
Gut microbiome and metabolome signatures in liver cirrhosis-related complications	24
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise	24
Acetyl-coenzyme A synthetase 2-mediated acetyl-coenzyme A accumulation promotes mitophagy and tumor growth via increased H3K27ac in hepatitis B virus-related hepatocellular carcinoma	24
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	23
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systemati	22
Letter to the editor: Clarifying Residual Drug Effects and Subgroup Outcomes in TDF-to-BSV Switch Trials	22
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”	22
DNMT1 Facilitates the Progression of MASLD by Impeding Transcription Mediated by HNF4α and PPARα	22
Reply to Correspondence to “Call for Preemptive Treatment of Cytomegalovirus in Patients with Cirrhosis and Acute Decompensation”	22
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with	21
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications	21
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?	21
Correspondence: Response to Editorial on “Extending MET–TRIB3 Axis Research in Hepatocellular Carcinoma: Immune Contexture and Patient Subgroups”	21
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound	20
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults	20
Screening strategy for non-alcoholic fatty liver disease	20
Regulation of hepatitis B virus cccDNA by metabolic pathways: Editorial on “GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome”	20
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	20
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma	20
Stratifying cholangiocarcinoma: tumor microenvironment, molecular drivers, and novel immunotherapeutic approaches	20
KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026	20
Depression and Suicide-Related Events Associated With Tenofovir Use in Chronic Hepatitis B: A Pharmacovigilance Analysis	20
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy	19
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation	19
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	19
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”	19
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis	19
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey	18
Harmonized ACLF Prognostication with Explainable Machine Learning Models: Traversing from Counts to Composition	18
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agon	18
PRMT1-mediated asymmetric dimethylation of arginine residue 602 in DDX1 promotes cholangiocarcinoma progression	18
Clinical implications of residual changes following HCV clearance: Editorial on “Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy”	18
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes	18
Challenges and Innovations in MASLD and T2DM: Strengthening Personalized Medicine with SGLT2 Inhibitors	18
The magic of sodium-glucose cotransporter-2 inhibitors (SGLT2-i) – Benefits in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2D)	17
Clinical Implications of Discordant FIB-4 and LSM in MASLD: Integrating Evidence and Optimizing Pathways — A Commentary on the Study by Rabbat et al.	17
vibraA non-invasive risk stratification tool for hepatitis B-related liver cirrhosis: The Baveno VI-SSM combined model: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related e	17
JCAD, a new potential therapeutic target in cholestatic liver disease	17
Rising burden of alcohol-associated liver disease and cancers: Insights into sex disparities and policy implications: Editorial on “Sex disparities in alcohol-associated liver disease and subtype diff	17
Reply to correspondence on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”	17
Extending MET–TRIB3 Axis Research in Hepatocellular Carcinoma: Immune Contexture and Patient Subgroups	17

Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?	17
ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling	16
Evidence-based hyponatremia management in liver disease	16
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease	16
From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by	15
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients	15
Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatiti	15
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences	15
Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	15
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues	15
Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization	14
Plasma Exchange and Abrogation of Monocyte Activation in Wilson’s Disease	14
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective	14
Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”	14
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease	14
Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and	14
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review	14
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease	13
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic	13
Roles of X-box binding protein 1 in liver pathogenesis	13
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”	13
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance	13
Non-alcoholic fatty liver disease: Definition and subtypes	13
COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling	13
Management of refractory ascites	13
Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma	13
The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma developme	12
Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]	12
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”	12
A Call for More Efforts to Incorporate Liver in the Metabolic Health Framework	12
The impact of ischemia-free liver transplantation on improving the prognosis of recipients using functionally marginal liver grafts: Editorial on “Ischemia-free liver transplantation improves the prog	12
Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”	12
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults	12
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults	12
Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”	11
Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters	11
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis	11
Clinical Implications of Discordant FIB-4 and LSM in MASLD: Integrating Evidence and Optimizing Pathways: Authors’ reply	11
Rethinking first-line screening in MASLD beyond the limitations of Fibrosis-4 index: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic	11
Congratulatory remarks	11
Letter to the editor on “HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study”	11
Early oxidative protein modifications and gut damage/leakiness contribute to drug-induced acute liver failure	11
Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer	10
Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”	10
Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD	10
Targeting the innate immune system in treating hepatitis B: prospects for functional cure	10
Acute hepatitis C virus infection: clinical update and remaining challenges	10
Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	10
Burden of Cardiovascular Complications in Steatotic Liver Disease in the United States	10
Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma	10
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis	10
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	10
Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes melli	10
Letter to the editor on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver dise	10
Hepatorenal syndrome: Current concepts and future perspectives	9
Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features	9
UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL	9
Letter to the editor 1 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”	9
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation	9
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives	9
Noncanonical EZH2 activity cooperates with FOXM1 to drive tumorigenesis and advanced progression in HCC	9
Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings	9
The latest global burden of liver cancer: A past and present threat	9
Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]	9
GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	9
Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis	8
Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen	8
Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma	8
Reply to “A Call for More Efforts to Incorporate Liver in the Metabolic Health Framework”	8
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials	8
Correspondence to Editorial 1 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”	8
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis	8
Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	8
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?	8
Correspondence to the Editorial “Aspirin on the prevention of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease”	8
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response	7
Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”	7
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”	7
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”	7
Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma	7
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antiv	7
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”	7
Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	7
Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults	7
Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan	7
Reply to correspondence on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”	7
Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”	7
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future	6
Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness	6
Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”	6
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply	6
Mechanistic Insights into a Noncanonical RAB25–GCN1 axis in ALD: Editorial on “RAB25/GCN1 signaling promotes ER stress to mediate alcohol-associated liver disease progression”	6
KASL clinical practice guidelines for management of autoimmune hepatitis 2022	6
Correspondence to editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”	6
HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C a	6